KYTX · Kyverna Therapeutics, Inc.

$8.32 -0.30 (-3.42%)

Russell 2000 member Rebalance outlook locked

Market Cap

$516.39M

61.84M

Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.

Filed	Seller	Relationship	Shares	Market Value	Approx. Sale	Broker
2026-04-17	KAREN WALKER	Officer	10,000	$95,300	2026-04-17	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-04-14	KAREN WALKER	Officer	2,459	$23,336	2026-04-14	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-04-07	DANIEL SPIEGELMAN	Director	17,578	$162,637	2026-04-07	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-31	DANIEL SPIEGELMAN	Director	16,634	$140,404	2026-03-31	Morgan Stanley Smith Barney LLC Executive Financial Services
2025-12-15	KAREN WALKER	Officer	23,998	$210,702	2025-12-15	Morgan Stanley Smith Barney LLC Executive Financial Services

Showing 1–5 of 5 filings

Key facts CIK 1994702 CUSIP 501976104 13F (30d) 97 filings 97 filers Visit website Investor relations